PNU-IMUNE 23 25 MCG / 0.5 ML
PNEUMOCOCCAL VACCINE POLYVALENT : 25 MCG / 0.5 ML · DIN 02230175 · LEDERLE LABS, DIVISION OF AMERICAN CYANAMID CO
Health Canada status: CANCELLED POST MARKET
What is PNU-IMUNE 23?
PNU-IMUNE 23 25 MCG / 0.5 ML contains PNEUMOCOCCAL VACCINE POLYVALENT : 25 MCG / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02230175, held by LEDERLE LABS, DIVISION OF AMERICAN CYANAMID CO, supplied as LIQUID for INTRAMUSCULAR ; SUBCUTANEOUS administration. Health Canada currently lists it as cancelled post market, status dated 06-Jun-2001. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02230175 |
|---|---|
| Brand name | PNU-IMUNE 23 |
| Generic / active ingredient | PNEUMOCOCCAL VACCINE POLYVALENT : 25 MCG / 0.5 ML |
| Manufacturer | LEDERLE LABS, DIVISION OF AMERICAN CYANAMID CO |
| Strength | 25 MCG / 0.5 ML |
| Dosage form | LIQUID |
| Route of administration | INTRAMUSCULAR ; SUBCUTANEOUS |
| Schedule | Schedule D |
| ATC code | J07AL02 PNEUMOCOCCUS, PURIFIED POLYSACC.ANTIGEN CONJUGATED |
| AHFS class | 80:12.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 06-Jun-2001 |
| Original market date | 1997-09-10 00:00:00 |
What can be used instead?
Other Canadian products sharing ATC code J07AL02 PNEUMOCOCCUS, PURIFIED POLYSACC.ANTIGEN CONJUGATED. 3 of 10 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CAPVAXIVE | 4 MCG / 0.5 ML | SOLUTION | MERCK CANADA INC | MARKETED | DIN 02549891 |
| PREVNAR 20 | 2.2 MCG / 0.5 ML | SUSPENSION | PFIZER CANADA ULC | MARKETED | DIN 02527049 |
| VAXNEUVANCE | 30 MCG / 0.5 ML | SUSPENSION | MERCK CANADA INC | MARKETED | DIN 02522403 |
| PNEUMO 23 | 25 MCG / 0.5 ML | LIQUID | SANOFI PASTEUR LIMITED | CANCELLED POST MARKET | DIN 02231259 |
| PNEUMOVAX 23 | 25 MCG / 0.5 ML | SOLUTION | MERCK CANADA INC | CANCELLED POST MARKET | DIN 00431648 |
| PNEUMOVAX 23 -(5-DOSE) | 25 MCG / 0.5 ML | SOLUTION | MERCK CANADA INC | CANCELLED POST MARKET | DIN 02240632 |
| PREVNAR | 20 MCG / 0.5 ML | SUSPENSION | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02244081 |
| PREVNAR 13 | 2.2 MCG / 0.5 ML | SUSPENSION | PFIZER CANADA ULC | CANCELLED POST MARKET | DIN 02335204 |
| SYNFLORIX | 3 MCG / 0.5 ML | SUSPENSION | GLAXOSMITHKLINE INC | CANCELLED POST MARKET | DIN 02320541 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.